ENGN (enGene Therapeutics) Tariff Resilience Score: 4/10 (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENGN enGene Therapeutics Inc ENGN
12 GF Score
Price $1.72
! 1 Warning Sign
View Full Analysis

What is enGene Therapeutics Tariff Resilience Score?

enGene Therapeutics ENGN +1.78% 12 Tariff Resilience Score is 4 as of Aug. 18, 2026. GuruFocus rates ENGN with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,362 Biotechnology companies, enGene Therapeutics ranks better than 52.72% on this metric.

enGene Therapeutics has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

enGene Therapeutics has enGene Holdings, involved in biotechnology, relies on global supply chains for raw materials. Tariffs on these imports can impact costs, and limited alternative suppliers increase vulnerability. However, industry-specific exemptions may offer some relief.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes enGene Therapeutics might have Average Resilient.

enGene Therapeutics  (NAS:ENGN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

enGene Therapeutics Tariff Resilience Score Related Terms

ENGN vs VTVT, GUTS, VXRT: Tariff Resilience Score Comparison

For the Biotechnology subindustry, enGene Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

enGene Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, enGene Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where enGene Therapeutics's Tariff Resilience Score falls into.


ENGN
12GF Score
enGene Therapeutics Inc ENGN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
enGene Therapeutics (ENGN) has a Tariff Resilience Score of 4 as of Aug. 18, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, enGene Therapeutics ranks #644 out of 1362 companies in the Biotechnology industry, placing it in the top 47.3%.
Is enGene Therapeutics' Tariff Resilience Score too high?
enGene Therapeutics' current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. enGene Therapeutics' value of 4 is 0% at this industry median. Based on the distribution chart, enGene Therapeutics ranks #644 out of 1362 companies in the Biotechnology industry, which is above the industry midpoint. Overall, enGene Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Tariff Resilience Score compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #644 out of 1362 companies for Tariff Resilience Score. This puts enGene Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. enGene Therapeutics' value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,362 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. enGene Therapeutics's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enGene Therapeutics's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (ENGN) has a current Tariff Resilience Score of 4. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. enGene Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For enGene Therapeutics (ENGN), the current Tariff Resilience Score is 4 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

enGene Therapeutics Business Description

Other Exchanges S0N0:Germany
Address 4868 Rue Levy, Suite 220, Saint-Laurent, QC, CAN, H4R 2P1
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
12GF Score

Get the complete analysis for ENGN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price